GLYCOMIMETICS INC
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
CBIO$13.65+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, · | ||||||||
| · · 2024 · · 2023 · | ||||||||
| | | | | | | | | |
| Revenue from collaboration and license agreements | | $— | | $10,000 | | | ||
| | | | | | | | | |
| Costs and expenses: | | | | | | | | |
| Research and development expense | | 14,259,756 | | 20,071,656 | | | ||
| General and administrative expense | | 18,249,318 | | 19,213,637 | | | ||
| Restructuring and asset impairment charges | | | 7,530,304 | | | — | | |
| Total costs and expenses | | 40,039,378 | | 39,285,293 | | | ||
| Loss from operations | | (40,039,378) | | (39,275,293) | | | ||
| | | | | | | | | |
| Other income | | | | | | | | |
| Gain on sale of asset | | | 1,224,945 | | | — | | |
| Interest income | | 935,275 | | 2,375,873 | | | ||
| Total other income | | | 2,160,220 | | | 2,375,873 | | |
| Net loss and comprehensive loss | | $(37,879,158) | | $(36,899,420) | | | ||
| Basic and diluted net loss per common share | | $(0.59) | | $(0.58) | | | ||
| Basic and diluted weighted-average number of common shares outstanding | | 64,477,249 | | 63,342,465 | | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.